Optimizing Treatment of Metastatic Breast Cancer Through Real-time Disease Monitoring


About this study

To identify subtype-specific signatures for breast cancer using genomic positioning of plasma DNA fragments. To validate changes in ctDNA levels as a biomarker for treatment monitoring in patients with metastatic breast cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Female adults ≥ 18 years of age.
  • Stage IV breast cancer undergoing cancer treatment.

Exclusion Criteria:

  • Stage I-III breast cancer.
  • Unwilling or unable to give consent.
  • Patients with a prior or concurrent malignancy, excluding non-melanoma skin cancers and non-invasive cancers whose natural history or treatment does not have the potential to interfere with the assessment of the investigational marker. 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Brenda Ernst, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer